-
2025-521391-58-00
4
2025-11-28
Asthma
-
2024-519976-19-00
5
2025-11-26
Asthma with type 2 inflammation characterized by an eosinophilic pheno
-
2024-519590-19-00
4
2025-11-25
PD-L1 positive advanced colorectal cancer
-
2024-519779-24-00
4
2025-11-25
VEXAS (VACUOLES, E1 ENZYME, X-LINKED, AUTOINFLAMMATORY, SOMATIC) syndr
-
2025-521511-40-00
10
2025-11-18
metastatic non-small cell lung cancer
-
2024-517553-26-00
5
2025-11-12
Advanced ALK-positive non-small cell lung cancer (NSCLC)
-
2023-506843-40-00
5
2025-10-29
Mycobacterium xenopi pulmonary infection
-
2024-519917-72-00
5
2025-10-29
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2024-518365-10-00
5
2025-10-28
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
-
2024-519495-83-00
4
2025-10-28
Digestive system diseases
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2024-519875-24-00
5
2025-09-26
Carcinoid syndrome
-
2024-516099-13-00
5
2025-09-25
Severe Irritable Bowel Syndrome (IBS)
-
2024-520386-31-00
5
2025-09-22
Locally Advanced Head & Neck Squamous Cell Carcinoma
-
2024-513613-12-00
9
2025-09-18
Part A: Healthy volunteers (Part A is not applicable to the EU; for in
-
2024-518325-15-00
5
2025-09-08
Gastroenteropancreatic neuroendocrine tumor (GEP-NET)
-
2024-519713-65-00
4
2025-09-04
Non-Small Cell Lung Cancer
-
2024-519152-82-00
5
2025-09-03
Relapsed/Refractory Follicular Lymphoma
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2024-517167-23-00
5
2025-08-28
Chronic Hepatitis D Infection
-
2024-515431-30-00
5
2025-08-14
Men treated with proctectomy for rectal cancer
-
2023-509630-19-00
5
2025-07-31
Esophageal Squamous Cell Carcinoma (ESCC)
-
2024-513589-20-00
9
2025-07-29
Treatment-resistant generalized Myasthenia Gravis
-
2024-515884-69-00
5
2025-07-16
Extensive Stage Small Cell Lung Cancer (ES-SCLC)